Background: The relative efficacy and safety of more potent P2Y12 inhibitors in patients with
acute coronary syndrome and high bleeding risk (HBR) undergoing percutaneous coronary …

Background Acute myocardial infarction (AMI) infrequently occurs after acute stroke. The
Heart‐brain team approach has a potential to appropriately manage this poststroke …

Background Previous studies have investigated a 1 to 6-month short dual antiplatelet
therapy (S-DAPT) after percutaneous coronary intervention (PCI) with modern drug eluting …

There is a paucity of data regarding the safety of a 1-month dual antiplatelet therapy (DAPT)
after percutaneous coronary intervention (PCI) in patients at high bleeding risk (HBR) …

Limited data exist on the temporal trend of major bleeding and its prediction by the
Academic Research Consortium-High Bleeding Risk (ARC-HBR) criteria in acute …

Background and aims The incidence and outcomes of high bleeding risk (HBR) patients in a
community cohort according to the Academic Research Consortium (ARC) criteria is not …

Antithrombotic therapy is the cornerstone for the treatment and prevention of ischemic
events among both acute (ACS) or chronic coronary syndromes (CCS)[1, 2]. Nevertheless …

We assessed the ability of predicting mortality and total in-hospital bleeding and adverse
outcomes by the Academic Research Consortium High Bleeding Risk (ARC-HBR) criteria in …

Historically, prevention from ischemic events with dual antiplatelet therapy (DAPT) post
percutaneous coronary intervention (PCI) took precedence over protection from bleeding …

BACKGROUND Cardiovascular disease, particularly myocardial infarction (MI) profound
impact on patients' quality of life and places a substantial burden on the healthcare and …